Literature DB >> 11894135

Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.

Valerie Sylvain1, Stephane Lafarge, Yves-Jean Bignon.   

Abstract

In order to generate an in vitro mouse model for the study of human ovarian cancers, we compared the effects of a truncated Brca1 mutant expression on cellular phenotype with those of a full-length sense and antisense Brca1 expression in the ID-8 mouse epithelial ovarian cancer cell line. The examined cellular processes include proliferation, tumorigenicity in syngeneic mice in vivo and sensitivity/resistance to several cytotoxic drugs. We found that the expression of a spontaneous truncated Brca1 mutant in ID-8 cells which contain two endogenous wild-type Brca1 alleles led to a dominant-negative effect of Brca1, demonstrated by an increase in tumorigenicity in vivo and in chemosensitivity. Expression of a truncated Brca1 mutant in a mouse epithelial ovarian cancer cell line could thus provide a powerful in vitro model for the study of human BRCA1-related ovarian tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11894135

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  22 in total

Review 1.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

2.  Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Authors:  David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson
Journal:  BJU Int       Date:  2011-07-14       Impact factor: 5.588

Review 3.  Nonsense-mediated mRNA Decay and Cancer.

Authors:  Maximilian W Popp; Lynne E Maquat
Journal:  Curr Opin Genet Dev       Date:  2017-11-07       Impact factor: 5.578

Review 4.  BRCAness: finding the Achilles heel in ovarian cancer.

Authors:  Georgios Rigakos; Evangelia Razis
Journal:  Oncologist       Date:  2012-06-06

5.  BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.

Authors:  P Tassone; P Tagliaferri; A Perricelli; S Blotta; B Quaresima; M L Martelli; A Goel; V Barbieri; F Costanzo; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

6.  BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.

Authors:  Katherine V Clark-Knowles; Anna M O'Brien; Johanne I Weberpals
Journal:  J Oncol       Date:  2010-02-22       Impact factor: 4.375

7.  BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells.

Authors:  Joshua D O'Donnell; Nicole C Johnson; Tracy D Turbeville; Michelle Y Alfonso; Patricia A Kruk
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-07-02       Impact factor: 2.416

Review 8.  Basal-like subtype and BRCA1 dysfunction in breast cancers.

Authors:  Yasuo Miyoshi; Keiko Murase; Koushi Oh
Journal:  Int J Clin Oncol       Date:  2008-10-23       Impact factor: 3.402

Review 9.  Organizing principles of mammalian nonsense-mediated mRNA decay.

Authors:  Maximilian Wei-Lin Popp; Lynne E Maquat
Journal:  Annu Rev Genet       Date:  2013       Impact factor: 16.830

10.  BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.

Authors:  Akiko Horiuchi; Cuiju Wang; Norihiko Kikuchi; Ryosuke Osada; Toshio Nikaido; Ikuo Konishi
Journal:  Biomark Insights       Date:  2007-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.